SUBSCRIBE: Print / Digital / eNewsletter
An efficacy evaluation comparing two marketed artificial tears showed that a polyethylene-based product (Systane Ultra, Alcon Laboratories) resulted in statisically greater reductions in corneal and conjunctival staining than a glycerin/carboxymethylcellulose-based tear (Refresh Optive, Allergan).
For patients who are suffering with moderate to severe signs and symptoms of seasonal or perennial allergic conjunctivitis, loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is a safe and well-tolerated therapeutic option that can provide rapid clinical improvement, according to new research.
A single sustained-release dexamethasone intravitreal implant resulted in resolution of inflammation and improvement in visual acuity (VA) in patients with intermediate or posterior uveitis through 26 weeks in a multicenter, randomized, controlled clinical trial.
An updated analysis of data from an ongoing phase II study of intravitreal ranibizumab treatment for diabetic macular edema shows that functional and anatomic benefits observed at 6-month primary efficacy endpoint are generally maintained at 1 year after switching to a "prn" dosing schedule.
Grid laser photocoagulation remains standard of care for eyes with ME secondary to BRVO.
Many approaches for treating exudative age-related macular degeneration (AMD) have been developed.
A preliminary study of epimacular brachytherapy showed that radiation and antivascular endothelial growth factor injections reduced the treatment burden in patients with neovascular age-related macular degeneration.
Alcon Laboratories' Independent Director Committee is calling Novartis' merger proposal "grossly inadequate," and it is vowing to fight Novartis in its efforts to take control.
Glaucoma and ocular hypertension can effectively be treated topically with IOP-lowering drops.
Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
